DDX17 and colorectal carcinoma: A study demonstrated that DDX17 promotes epithelial-mesenchymal transition and metastasis via the miR-149-3p/CYBRD1 pathway in colorectal cancer (CRC) patients, which significantly contributes to aggressive progression and prognosis of CRC [9].